- 2017,
Skolnick re-retired from NIH to
serve as
Chief Scientific Officer of
Opiant Pharmaceuticals, Inc.—manufacturers of the
Narcan nasal spray device. Ricks...
-
under development by Sanofi-Aventis. In late 2018, the drug was
licensed by
Opiant Pharmaceuticals,
which intends to
develop it for the
treatment of acute...
-
original on 1
December 2017.
Retrieved 20
November 2017. "Teva
Invalidates Opiant Patents In
Narcan Suit - Law360". www.law360.com.
Archived from the original...
- the
Santa Monica-headquartered, NASDAQ-listed
biopharmaceutical company,
Opiant. In July 2023
Indivior paid $20.4
million to C4X
Discovery for the full...
- on 7
November 2021.
Retrieved 1
November 2021. "Intranasal
nalmefene -
Opiant Pharmaceuticals". AdisInsight.
Springer Nature Switzerland AG. Archived...
-
Sinclair was the
chief science officer with
Lightlake Therapeutics (now
named Opiant Pharmaceuticals,
researching using a
similar method for the
treatment of...
-
Roger Crystal, the
chief executive officer of
Lightlake Therapeutics (now
Opiant Pharmaceuticals),
teamed to
develop an
intranasal version of the drug. NIDA...
- Technologies/Pfizer
Nanotherapeutics Neumedicines (former)
Novartis Vaccines (former)
Opiant Pfenex Roche Romark Laboratories, L.C. (former)
Sanofi Pasteur (former)...
